| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | aripiprazole monohydrate (Abilify Maintena®) |
| Formulation | 300 mg and 400 mg powder and solvent for prolonged-release suspension for (deltoid) injection |
| Reference number | 2667 |
| Indication | Maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole |
| Company | Otsuka Pharmaceutical (UK) Ltd |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 19/03/2015 |